These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 7749307)
1. Screening methodologies for the discovery of novel cytotoxic antitumor agents. Casazza AM; Long BH Biotechnology; 1994; 26():281-300. PubMed ID: 7749307 [No Abstract] [Full Text] [Related]
2. Mechanism-based screening for the discovery of novel antifungals. Kirsch DR; DiDomenico BJ Biotechnology; 1994; 26():177-221. PubMed ID: 7749303 [No Abstract] [Full Text] [Related]
3. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Lavergne O; Harnett J; Rolland A; Lanco C; Lesueur-Ginot L; Demarquay D; Huchet M; Coulomb H; Bigg DC Bioorg Med Chem Lett; 1999 Sep; 9(17):2599-602. PubMed ID: 10498216 [TBL] [Abstract][Full Text] [Related]
4. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents. Terada T; Fujimoto K; Nomura M; Yamashita J; Kobunai T; Takeda S; Wierzba K; Yamada Y; Yamaguchi H Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2720-7. PubMed ID: 1334447 [TBL] [Abstract][Full Text] [Related]
5. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. Vicker N; Burgess L; Chuckowree IS; Dodd R; Folkes AJ; Hardick DJ; Hancox TC; Miller W; Milton J; Sohal S; Wang S; Wren SP; Charlton PA; Dangerfield W; Liddle C; Mistry P; Stewart AJ; Denny WA J Med Chem; 2002 Jan; 45(3):721-39. PubMed ID: 11806724 [TBL] [Abstract][Full Text] [Related]
6. Structure-based drug design: from nucleic acid to membrane protein targets. Dailey MM; Hait C; Holt PA; Maguire JM; Meier JB; Miller MC; Petraccone L; Trent JO Exp Mol Pathol; 2009 Jun; 86(3):141-50. PubMed ID: 19454265 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. Leteurtre F; Kohlhagen G; Paull KD; Pommier Y J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892 [TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Pommier Y Cancer Chemother Pharmacol; 1993; 32(2):103-8. PubMed ID: 8387398 [No Abstract] [Full Text] [Related]
10. Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11. Saulnier MG; Balasubramanian BN; Long BH; Frennesson DB; Ruediger E; Zimmermann K; Eummer JT; St Laurent DR; Stoffan KM; Naidu BN; Mahler M; Beaulieu F; Bachand C; Lee FY; Fairchild CR; Stadnick LK; Rose WC; Solomon C; Wong H; Martel A; Wright JJ; Kramer R; Langley DR; Vyas DM J Med Chem; 2005 Apr; 48(7):2258-61. PubMed ID: 15801816 [TBL] [Abstract][Full Text] [Related]
11. Immunomodulators. Okuhara M; Kino T Biotechnology; 1994; 26():321-46. PubMed ID: 7749311 [No Abstract] [Full Text] [Related]
12. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578 [TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Chang JY; Hsieh HP; Pan WY; Liou JP; Bey SJ; Chen LT; Liu JF; Song JS Biochem Pharmacol; 2003 Jun; 65(12):2009-19. PubMed ID: 12787881 [TBL] [Abstract][Full Text] [Related]
14. Natural products from marine invertebrates and microbes as modulators of antitumor targets. Newman DJ; Cragg GM Curr Drug Targets; 2006 Mar; 7(3):279-304. PubMed ID: 16515528 [TBL] [Abstract][Full Text] [Related]
15. A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study. Karki R; Jun KY; Kadayat TM; Shin S; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES Eur J Med Chem; 2016 May; 113():228-45. PubMed ID: 26945111 [TBL] [Abstract][Full Text] [Related]
16. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906 [No Abstract] [Full Text] [Related]
18. Inhibition of topoisomerases by antitumor prostaglandins. Suzuki K; Shono F; Uyeda M Biosci Biotechnol Biochem; 1998 Oct; 62(10):2073-5. PubMed ID: 9836448 [TBL] [Abstract][Full Text] [Related]
19. A high-throughput model for screening anti-tumor agents capable of promoting polymerization of tubulin in vitro. Hu W; Dong H; Li YZ; Hu XT; Han GJ; Qu YB Acta Pharmacol Sin; 2004 Jun; 25(6):775-82. PubMed ID: 15169631 [TBL] [Abstract][Full Text] [Related]